The first results with the thalidomide treatment in the Czech Republic;První zkušenostis léčbou mnohočetněho myelomu v Českě Republice

Klinicka Onkologie

Volumn 15, Issue SUPPL., 2002, Pages 42-43

  Spicka I ^a   Hajek R ^a   Gregora, E ^a   Straub, J ^a   Foldyna, D ^a   Jankovska M ^a   Kamelander, J ^a   Neuwirtova R ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; Myeloma; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; DEXAMETHASONE; IMMUNOMODULATING AGENT; THALIDOMIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; CZECH REPUBLIC; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUTROPENIA; PARESTHESIA; POLYNEUROPATHY; QUALITY OF LIFE; SOMNOLENCE; THROMBOCYTOPENIA;

EID: 0036032468     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Singhal S, Mehta J.: Thalidomide in cancer. Biomed Pharmacother. 2002 Feb;56(1):4-12.
2. Munshi NC, Wilson C.: Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol. 2001 Dec;28(6):565-9.
3. Gupta D, Treon SP, Shima Y, et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia. 2001 Dec; 15 (12): 1950-61.
4. Dmoszynska A, Bojarska-Junak A, Domanski D., et al.: Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma. 2002 Feb;43(2):401-6.
5. Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-71.
6. Neben K., Moehler T., Egerer G.: High plasma basic fibroblast growth factor concentration is associated with response tothlidomide in progressive multiple myeloma. Blood. 2000 96:11 (abstr 721)
7. Hideshima T, Chauhan D, Podar K, et al.: Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol. 2001 Dec;28(6):607-12. Review.
8. Davies FE, Raje N, Hideshima T, et al.: Thalidomide and immuno-modulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 2001 Jul 1;98(1):210-6.
9. Mitsiades N, Mitsiades CS, Poulaki V, et al: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 1;99(11):4079-86.
10. Garcia-Sanz R, Gonzalez-Fraile MI, et al.: The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J. 2002;3(1):43-8.
11. Rajkumar S.V.: Angiogenesis and Anti-angiogenic Therapy with Thalidomide for Myeloma. VIIIth International Myeloma Workshop, Banff, 2001, abstract book, p. 112
12. Shaugnessy J., Zhan F., Tian E. et al: Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and ImdD. Blood 2001 96:11 (abstr.2485)
13. ohnston RE, Abdalla SH.: Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma. 2002 Feb;43(2):351-4.
14. Zangari M., Anaissie E., Barlogie B. et al.: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-5